Asaf Danziger - 28 Jun 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Executive Officer, Director
Signature
Steven Robbins, as attorney in fact for Danziger, Asaf
Issuer symbol
NVCR
Transactions as of
28 Jun 2024
Net transactions value
+$15,165
Form type
4
Filing time
06 Aug 2024, 16:19:58 UTC
Previous filing
06 Jul 2023
Next filing
03 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $15,165 +1,239 +8.9% $12.24 15,228 28 Jun 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024.